GlassScriptPhysician profile
John C Siano
NPI 1689628067
$10,340.98
in general payments reported to CMS, 2019-2025
63 companies · $2,143 in 2025
The $2,143 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,306 · 2020: $1,295 · 2021: $1,179 · 2022: $1,498 · 2023: $1,173 · 2024: $1,746 · 2025: $2,143.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,062.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,062.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,111.22 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Pfizer INC. | $1,044.43 | 2019-2025 | |
| Lilly USA, LLC | $855.61 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Abbvie INC. | $727.66 | 2021-2025 | Vraylar, Ubrelvy |
| Amgen INC. | $664.53 | 2019-2025 | Evenity, Repatha, Prolia |
| Glaxosmithkline, LLC. | $542.54 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $530.96 | 2019-2025 | Jardiance |
| Viiv Healthcare Company | $364.54 | 2024-2025 | Dovato, Rukobia, Apretude |
| Otsuka America Pharmaceutical, INC. | $307.44 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Bayer Healthcare Pharmaceuticals INC. | $298.51 | 2021-2025 | |
| Abbott Laboratories | $293.18 | 2022-2025 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $246.72 | 2019-2024 | Delstrigo, Pifeltro, Dificid |
| Biohaven Pharmaceutical Holding Company LTD. | $233.46 | 2022 | |
| Novartis Pharmaceuticals Corporation | $220.05 | 2019-2024 | |
| Biohaven Pharmaceuticals, INC. | $206.75 | 2021 |
Show all 63 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Siano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.